TIGER: Novel intestinal topical agonists of the TGR5 bile acids receptor for the treatment of the Type 2 diabetes and its metabolic complications
Description
Activation of TGR5 receptor is recognized for stimulating the secretion of incretin GLP1.
Increased secretion of GLP 1 is used as a treatment of type 2 diabetes thanks to GLP-like products (Victoza, Byetta)
Benefits:
- Topical Molecules (very low systemic leakage)
- POC in vivo for the secretion of endogenous GLP-1, improvement of insulin resistance, fasting glycemia and insulinemia, and weight lost in acute and chronic administration in diabetic mice model.
- Orally active
- No toxic effect, particularly on gallbladder
Sheet
Download the offer